Aon Faces Challenges With Integration Risks And Slow Growth: BofA Downgrades Stock

BofA Securities analyst downgrades Aon plc to Underperform, citing underperformance, integration risk, and management changes. $306 price target.

BofA Securities analyst Grace Carter downgraded Aon plc (NYSE:AON) to Underperform from Neutral and cut the price target from $345 to $306.

The analyst writes that AON has recently underperformed the insurance broker peer group owing to below-average organic growth, integration risk from the $13.4 billion NFP acquisition, and management changes. 

Notably, since 2H22, Aon’s Commercial Risk Solutions segment has reported organic revenue growth in the 3%- 6% range , compared to comparable peer results averaging 7%- 10%, says the analyst. 

Carter projects gradual improvement in organic growth but concedes a downside compared to the estimates if current challenges persist more than expected.

The analyst says re-establishing investor confidence could take time for the company, slowing a return to historical valuation levels.

The analyst sees EPS of $11.93 for FY24 and $14.83 for FY25, sharply below the consensus.

In April, AON reported first quarter FY24 adjusted EPS of $5.66, missing the consensus of $5.91 and sales of $4.070 billion, coming below the street view of $4.126 billion. 

Investors can gain exposure to the stock via Litman Gregory Funds Trust Polen Capital International Growth ETF (NYSE:PCIG) and Hennessy Stance ESG ETF (NYSE:STNC).

Also Read: Aon Analysts Slash Their Forecasts After Downbeat Earnings

Price Action: AON shares are down 1.51% at $285.61 at the last check Wednesday. 

Photo via Shutterstock

Total
0
Shares
Related Posts
Read More

Google Parent Alphabet Eyes HubSpot Acquisition: Bloomberg

Alphabet Inc (NASDAQ:GOOGL) eyes HubSpot Inc. (NYSE: HUBS) in a strategic move poised to reshape the CRM sector. With HubSpot's soaring market capitalization and Alphabet's vision to bolster its CRM foothold, the potential acquisition signals a significant shift in the tech landscape. Amidst the surge in HubSpot's shares, Alphabet's interest underscores its commitment to diversify and compete against CRM giants like Microsoft Corp (NASDAQ:MSFT) and Salesforce Inc (NYSE:CRM).

CRM

Read More

Cannabinoids & Autism Spectrum Disorder: This Baltimore Company Is On Track To Start Phase 2 Clinical Trial For New Treatment

Cannabinoid-focused biopharmaceutical company Greater Cannabis Company, Inc. (OTC: GCAN) has submitted a clinical trial application to the Israel Ministry of Health for approval of Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy.

GCAN